(RTTNews) - Structure Therapeutics Inc. (GPCR) shares are falling more than 51 percent on Monday morning trade, on reports that its weight loss and diabetes drug GSBR-1290's performance was weaker than its rival Eli Lilly's orforglipron at eight weeks.
GSBR -1290 demonstrated a clinically meaningful decrease in weight, or 4.74 percent higher than placebo.
Currently, GPCR shares are at $28.16, down 52.40 percent from the previous close of $59.16 on a volume of 2,354,862.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
